Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
ખોલો
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.21%
1,091.51
-2.30
-0.21%
—1,093.811,096.521,100.221,091.51——
SIXC
Communications
SIXC
Communications
SIXC
+0.22%
610.11
+1.34
+0.22%
—608.77608.77612.97608.77——
SIXE
Energy
SIXE
Energy
SIXE
-1.34%
1,237.98
-16.83
-1.34%
—1,254.811,253.011,253.871,226.33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.93%
1,744.71
-16.40
-0.93%
—1,761.111,764.271,766.881,744.71——
SIXM
Financials
SIXM
Financials
SIXM
-0.37%
640.18
-2.40
-0.37%
—642.58644.87648.48640.18——
SIXR
Staples
SIXR
Staples
SIXR
-0.18%
849.58
-1.55
-0.18%
—851.13855.66858.75845.56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.23%
217.48
-0.50
-0.23%
—217.98217.98218.65216.88——
SIXT
Technology
SIXT
Technology
SIXT
+1.52%
3,260.69
+48.86
+1.52%
—3,211.833,227.213,268.383,226.55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.69%
942.45
-6.53
-0.69%
—948.98948.58957.83941.97——
SIXV
Health care
SIXV
Health care
SIXV
-0.52%
1,466.80
-7.72
-0.52%
—1,474.521,479.031,481.041,466.80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.22%
2,397.50
+5.38
+0.22%
—2,392.122,396.952,421.222,382.32——
LGND:NASDAQ
Ligand Pharmaceuticals Inc
US$227.44
-0.88%
(-2.01) 1D
US$227.44
0.00% (0.00)
After hours
Closed: 1 મે, 04:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LGND...
ખોલો
US$229.87
High
US$236.22
Low
US$226.46
Mkt. cap
૪.૫૬ અબજ
Avg. vol.
૨.૫૦ લાખ
Volume
૨.૩૫ લાખ
P/E ratio
૩૭.૦૯
52-wk high
US$238.31
52-wk low
US$98.89
EPS
US$6.13
Beta
૧.૦૬
Shares outstanding
૨.૦૦ કરોડ
No. of employees
૪૭
News stories
From sources across the web
Stock Titan
Stock Titan
·
11 કલાક પહેલાં
LGND (NASDAQ) Rule 144 notice lists 467 common shares and dated sales
Stock Titan
Stock Titan
·
18 કલાક પહેલાં
Vanguard Capital Management files Schedule 13G on Ligand (LGND) showing 5% stake
GuruFocus
GuruFocus
·
1 દિવસ પહેલાં
LGND Maintained by HC Wainwright & Co. -- Price Target Raised to $289
Zacks Small Cap Research
Zacks Small Cap Research
·
2 દિવસ પહેલાં
LGND: XOMA Buy Adds 100+ Assets
પ્રોફાઇલ
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
About Ligand Pharmaceuticals Inc
CEO-
Employees47
Foundedસપ્ટે 1987
HeadquartersJupiter, ફ્લોરિડા, સંયુકત રાજ્ય અમેરિકા
Sector-
Websiteligand.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
માર્ચ 2025
જૂન 2025
સપ્ટે 2025
ડિસે 2025
Revenue
4.53 કરોડ
4.76 કરોડ
11.55 કરોડ
5.97 કરોડ
Cost of goods sold
5.49 કરોડ
94.74 લાખ
2.48 કરોડ
65.03 લાખ
Cost of revenue
5.49 કરોડ
94.74 લાખ
2.48 કરોડ
65.03 લાખ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.88 કરોડ
2.02 કરોડ
2.84 કરોડ
2.50 કરોડ
Operating expense
2.71 કરોડ
2.84 કરોડ
3.65 કરોડ
3.31 કરોડ
Total operating expenses
8.20 કરોડ
3.79 કરોડ
6.14 કરોડ
3.96 કરોડ
Operating income
-3.67 કરોડ
97.20 લાખ
5.41 કરોડ
2.00 કરોડ
Other non operating income
-20.58 લાખ
96.00 હજાર
3.90 લાખ
14.83 લાખ
EBT including unusual items
-5.02 કરોડ
1.12 કરોડ
14.11 કરોડ
5.68 કરોડ
EBT excluding unusual items
-3.78 કરોડ
1.03 કરોડ
5.75 કરોડ
11.68 કરોડ
Income tax expense
-77.29 લાખ
63.76 લાખ
2.39 કરોડ
1.20 કરોડ
Effective tax rate
15.40%
56.81%
16.91%
21.13%
Other operating expenses
-
-
-
-
Net income
-4.25 કરોડ
48.47 લાખ
11.73 કરોડ
4.48 કરોડ
Net profit margin
-93.64%
10.18%
101.57%
75.06%
Earnings per share
1.33
1.60
3.09
2.02
Interest and investment income
17.71 લાખ
16.21 લાખ
38.74 લાખ
63.93 લાખ
Interest expense
-8.67 લાખ
-11.53 લાખ
-9.10 લાખ
-17.85 લાખ
Net interest expenses
9.04 લાખ
4.68 લાખ
29.64 લાખ
46.08 લાખ
Depreciation and amortization charges
-
-
-
-
EBITDA
-2.84 કરોડ
1.78 કરોડ
6.33 કરોડ
2.83 કરોડ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer